Anand Rathi said Glenmark Life has leadership in select high-value non-commercialized APIs in chronic therapeutic areas. It said the has cost leadership, a strong balance sheet, a growing business, and a high return on net worth (RoNW) of 46.71 per per cent. Add to that are reasonable valuations, which the brokerage said made it suggest a 'subscribe' on the issue. Geojit Financial Services called the IPO fairly priced and suggested a 'Subscribe' for a long-term basis, considering Glenmark's strong focus on research and development (R&D), its expansion plans, the growth opportunity ahead in CDMO (contract development and manufacturing operations) services and expanding of complex API portfolio.